Predict your next investment

Venture Capital
vitalvc.com

See what CB Insights has to offer

Investments

15

Portfolio Exits

4

About Vital Venture Capital

Vital Venture Capital is a venture capital firm based in Bethesda, Maryland, focusing on patentable science technologies and business software. The firm has invested in 17 portfolio companies since its formation in 2008. Partners contribute expertise in marketing, sales, implementation, product development, intellectual property, and finance to the management teams of their investment companies.

Vital Venture Capital Headquarter Location

7101 Wisconsin Avenue Suite 1210

Bethesda, Maryland, 20814,

United States

415-297-6451

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vital Venture Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Vital Venture Capital in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Vital Venture Capital News

RubrYc Therapeutics Completes $10M Million Series A Financing

Apr 12, 2018

RubrYc Therapeutics Completes $10M Million Series A Financing SAN RAMON, Calif., April 11, 2018-- RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it has closed a $10 million Series A Preferred Equity financing round led by Third Point Ventures, with participation by Paladin Capital Group and Vital Venture Capital. "Our development of unique chemical libraries has allowed us to map the surfaces of drug targets with unprecedented resolution, and to identify off target binding events that hamper drug discovery and development," said Dr. Isaac Bright, CEO of RubrYc Therapeutics. "With our Series A financing, which completes our spin-off from HealthTell, Inc., we are continuing to build our antibody discovery platform, proprietary pipeline of therapeutic candidates, and actively initiating new pharmaceutical partnerships." RubrYc is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery. The company will be collaborating with biotechnology companies in early drug discovery and developing its own molecules. "I am excited to launch RubrYc Therapeutics and believe that the company's applications of our technology address important challenges in antibody characterization. We are already seeing results in the earliest phases of RubrYc programs, and I look forward to supporting the team as the company grows," said Bill Colston, CEO of HealthTell and Executive Chairman of RubrYc Therapeutics. About RubrYc Therapeutics Founded in 2017, RubrYc Therapeutics, Inc. emerged as a biotherapeutic discovery partner of immunomics leader HealthTell, Inc. The Company has exclusive rights to HealthTell technology and combines binding information from diverse chemical library assays, with gold-standard drug discovery methods to develop biotherapeutic candidates that are optimized for clinical development. Contact:

Vital Venture Capital Investments

15 Investments

Vital Venture Capital has made 15 investments. Their latest investment was in Ginkgo Bioworks as part of their Series E on September 9, 2019.

CBI Logo

Vital Venture Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/19/2019

Series E

Ginkgo Bioworks

$290M

No

32

4/11/2018

Series A

RubrYc Therapeutics

$10M

Yes

5

12/14/2017

Series D

Ginkgo Bioworks

$275M

Yes

15

3/9/2016

Series B

Subscribe to see more

$99M

Subscribe to see more

10

1/19/2016

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/19/2019

4/11/2018

12/14/2017

3/9/2016

1/19/2016

Round

Series E

Series A

Series D

Series B

Series D

Company

Ginkgo Bioworks

RubrYc Therapeutics

Ginkgo Bioworks

Subscribe to see more

Subscribe to see more

Amount

$290M

$10M

$275M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

32

5

15

10

10

Vital Venture Capital Portfolio Exits

4 Portfolio Exits

Vital Venture Capital has 4 portfolio exits. Their latest portfolio exit was Ginkgo Bioworks on September 17, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/17/2021

Reverse Merger

$99M

10

9/12/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/31/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

11/11/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/17/2021

9/12/2019

10/31/2018

11/11/2015

Exit

Reverse Merger

IPO

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

10

10

10

10

Vital Venture Capital Team

1 Team Member

Vital Venture Capital has 1 team member, including current Founding Partner, David Phelps.

Name

Work History

Title

Status

David Phelps

Founding Partner

Current

Name

David Phelps

Work History

Title

Founding Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.